Nasal absorption of metoclopramide from different Carbopol® 981 based formulations: In vitro, ex vivo and in vivo evaluation☆

Taş, Çetin; Özkan, Cansel Köse; Savaşer, Ayhan; Özkan, Yalçın; Taşdemir, Umut; Altunay, Hikmet

doi:10.1016/j.ejpb.2006.05.017

Cited by 77 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The absorption is diminished owing to a reduced diffusion of drug from the viscous formulation (Bahadur & Pathak, 2012b). In contrast, it has also been reported that the larger therapeutic period of nasal formulations were achieved with elevated viscosity (Tas et al, 2006;Pisal et al, 2012).…”

Section: Viscositymentioning

confidence: 84%

Nasal-nanotechnology: revolution for efficient therapeutics delivery

2014

View full text Add to dashboard Cite

Context: In recent years, nanotechnology-based delivery systems have gained interest to overcome the problems of restricted absorption of therapeutic agents from the nasal cavity, depending upon the physicochemical properties of the drug and physiological properties of the human nose. Objective: The well-tolerated and non-invasive nasal drug delivery when combined with the nanotechnology-based novel formulations and carriers, opens the way for the effective systemic and brain targeting delivery of various therapeutic agents. To accomplish competent drug delivery, it is imperative to recognize the interactions among the nanomaterials and the nasal biological environment, targeting cell-surface receptors, drug release, multiple drug administration, stability of therapeutic agents and molecular mechanisms of cell signaling involved in patho-biology of the disease under consideration. Methods: Quite a few systems have been successfully formulated using nanomaterials for intranasal (IN) delivery. Carbon nanotubes (CNTs), chitosan, polylactic-co-glycolic acid (PLGA) and PLGA-based nanosystems have also been studied in vitro and in vivo for the delivery of several therapeutic agents which shown promising concentrations in the brain after nasal administration. Results and conclusion: The use of nanomaterials including peptide-based nanotubes and nanogels (NGs) for vaccine delivery via nasal route is a new approach to control the disease progression. In this review, the recent developments in nanotechnology utilized for nasal drug delivery have been discussed.

show abstract

Section: Viscositymentioning

confidence: 84%

Nasal-nanotechnology: revolution for efficient therapeutics delivery

2014

View full text Add to dashboard Cite

show abstract

“…Use of nanoparticles, mucoadhesive agents, absorption enhancers, surfactants, lipid emulsions, vasoconstrictors and efflux transporter inhibitors are some of the potential approaches to reduce the clearance and enhance the residence time [29][30][31][32][33][34][35][36][37].…”

Section: Nanoparticular Delivery Systemmentioning

confidence: 99%

Recent Updates in the Formulation Strategies to Enhance the Bioavailability of Drugs Administered via Intranasal Route

Dudhipala¹,

Narala²,

Bomma³

2016

J Bioequiv Availab

View full text Add to dashboard Cite

“…The flux at steady-state across the mucosa was calculated from the slope of the linear part of the line obtained by plotting mass transported per unit area against time (Tas et al, 2006).…”

Section: Ex Vivo Permeation Through Sheep Nasal Mucosamentioning

confidence: 99%

Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies

et al. 2017

View full text Add to dashboard Cite

Being one of the highly effective drugs in treatment of Alzheimer's disease, Rivastigmine brain targeting is highly demandable, therefore liposomal dispersion of Rivastigmine was prepared containing 2 mol% PEG-DSPE added to Lecithin, Didecyldimethyl ammonium bromide (DDAB), Tween 80 in 1:0.02:0.25 molar ratio. A major challenge during the preparation of liposomes is maintaining a stable formulation, therefore the aim of our study was to increase liposomal stability by addition of DDAB to give an electrostatic stability and PEG-DSPE to increase stability by steric hindrance, yielding what we called an electrosteric stealth (ESS) liposomes. A medium nano-sized liposome (478 ± 4.94 nm) with a nearly neutral zeta potential (ZP, À8 ± 0.2 mV) and an entrapment efficiency percentage of 48 ± 6.22 was prepared. Stability studies showed no major alteration after three months storage period concerning particle size, polydispersity index, ZP, entrapment efficiency and in vitro release study confirming the successful formation of a stable liposomes. No histopathological alteration was recorded for ESS liposomes of the sheep nasal mucosa. While ESS liposomes showed higher % of drug permeating through the sheep nasal mucosa (48.6%) than the drug solution (28.7%). On completing the in vivo pharmacokinetic studies of 36 rabbits showed 424.2% relative bioavailability of the mean plasma levels of the formula ESS compared to that of RHT intranasal solution and 486% relative bioavailability of the mean brain levels. KeywordsRivastigmine, pegylated liposomes, Tween 80, ex vivo permeation, in vivo pharmacokinetic studies History

show abstract

Nasal absorption of metoclopramide from different Carbopol® 981 based formulations: In vitro, ex vivo and in vivo evaluation☆

Cited by 77 publications

References 29 publications

Nasal-nanotechnology: revolution for efficient therapeutics delivery

Nasal-nanotechnology: revolution for efficient therapeutics delivery

Recent Updates in the Formulation Strategies to Enhance the Bioavailability of Drugs Administered via Intranasal Route

Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies

Contact Info

Product

Resources

About